lifestyle.massnews.com

Author: Norgine Limited

Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union

April 29, 2026
Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales

March 5, 2026
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology

December 18, 2025